Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04866017
Title A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors BeiGene
Age Groups: adult | senior
Covered Countries USA | AUS

Additional content available in CKB BOOST